| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8750871 | Respiratory Investigation | 2016 | 6 Pages |
Abstract
Although the survival benefit with afatinib remains unclear, our observational analysis demonstrated the feasibility of using afatinib for EGFR-mutated NSCLC in clinical practice. In particular, a relatively high level of drug delivery is possible. In addition, a lower BSA may be a predictor of diarrhea in patients treated with afatinib.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology and Microbiology (General)
Authors
Yosuke Wada, Shigeru Koyama, Hiroshi Kuraishi, Takashige Miyahara, Fumiaki Yoshiike, Toshihiko Agatsuma, Ryouhei Yamamoto, Yasushi Ono, Toshiro Suzuki, Tsutomu Hachiya, Daisuke Gomi, Kazunari Tateishi, Masayuki Hanaoka, Tomonobu Koizumi,